Increased angiotensin II is associated with muscle atrophy in CKD [34] and RASi drug use decelerates the decline of renal function, which may explain the benefit in the mobility and usual care dimensions associated with RASi drug use in this cohort. The gene discussed is AGT; the disease is muscle atrophy.